Overview
Rimonabant is a synthetic cannabinoid receptor antagonist that specifically targets the CB1 receptor subtype. Developed by Sanofi-Aventis, it was initially approved in Europe in 2006 as an anti-obesity drug under the brand name Acomplia. The compound gained attention for its unique mechanism of action in the endocannabinoid system. While withdrawn from clinical use due to psychiatric side effects, rimonabant remains valuable in research settings. It serves as a reference standard in cannabinoid receptor studies and continues to be investigated for potential therapeutic applications in various neurological conditions.
Physical and Chemical Properties
Rimonabant appears as a white to off-white crystalline powder with a melting point around 200-202°C. The compound is characterized by its high lipophilicity, which influences its pharmacokinetic properties. Its molecular structure features a central pyrazole ring with chlorophenyl and carboxamide substituents. The substance shows good solubility in dimethyl sulfoxide (DMSO) and limited solubility in ethanol, while being practically insoluble in water. This solubility profile necessitates careful consideration when preparing solutions for experimental use. The compound's stability is optimal when stored in cool, dry conditions protected from light.
Main Applications
Rimonabant's primary current application is as a research tool in neuroscience and metabolic studies. Scientists use it to investigate the endocannabinoid system's role in appetite regulation, addiction, and pain perception. The compound serves as a gold standard CB1 antagonist in pharmacological experiments. In its former clinical application, rimonabant was prescribed for obesity management, demonstrating effectiveness in weight reduction and metabolic parameter improvement. However, its use was discontinued due to concerns about depression and suicidal ideation risks. Some researchers continue to explore its potential in treating nicotine addiction and other substance use disorders.
Safety and Storage
Rimonabant requires careful handling due to its pharmacological activity and potential health effects. Laboratory personnel should use appropriate personal protective equipment, including gloves and safety glasses, when working with the substance. Work should be conducted in a well-ventilated area or fume hood. For storage, maintain the compound in its original container at 2-8°C, protected from light and moisture. Proper labeling is essential, and the material should be kept secured when not in use. Researchers should be aware of local regulations regarding controlled substances, as rimonabant may be subject to special restrictions in some jurisdictions.
B2B Procurement Guide
When procuring rimonabant for research purposes, buyers should verify the supplier's credentials and the product's certification of analysis. Reputable suppliers should provide detailed documentation including purity (typically ≥98% for research use), batch number, and expiration date. Consider ordering small quantities initially to verify quality, especially when switching suppliers. Lead times may vary depending on regulatory requirements in different countries. For international shipments, ensure all necessary import permits are obtained in advance. Some suppliers offer customized packaging options for bulk orders, which can be cost-effective for long-term research projects.
Related Manufacturers
- 主营：盐酸利莫那班、莪术二酮、人参皂苷rc
- 主营：硫酸汞、硝酸汞、雷尼镍、利莫那班分析纯、二十烷、丁二酸、硫化银、正己醇、硫酸镉、铋酸钠、苯甲醇、硅酸钠、正辛酸、硫酸镁、磷钨酸、滑石粉、草酸锡、蓖麻油、椰子油、钒试剂、异辛醇